Skip to main content

MIMEDX Announces Launch of EPIXPRESS®

Written by Customer Service on . Posted in Public Companies.

Next-Generation, Lyophilized Human Placental Allograft Further Expands Company’s Broad Portfolio of Advanced Wound Care (“AWC”) Products

MARIETTA, Ga., Oct. 06, 2025 (GLOBE NEWSWIRE) — MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the launch of EPIXPRESS®, the Company’s newest addition to its portfolio of AWC solutions.

“I am pleased to announce our latest, organically developed addition to our product portfolio today with the launch of EPIXPRESS,” said Joseph H. Capper, MIMEDX Chief Executive Officer. “With EPIXPRESS, our R&D team has built upon the fantastic attributes the market loves about EPIEFFECT by incorporating fenestrations to allow for fluid movement through the tissue. A hallmark of our success has been, and will continue to be, a commitment to market-driven innovation.”

EPIXPRESS expands MIMEDX’s PURION®-processed placental allograft offering aimed at helping clinicians treat acute and chronic, hard-to-heal wounds. Like EPIEFFECT, EPIXPRESS is a lyophilized product, and features a thick, tri-layer configuration. Additionally, EPIXPRESS adds fenestrations to the sheet configurations to help with fluid movement. EPIXPRESS can be used on a wide range of common conditions, such as diabetic foot ulcers (“DFUs”) and venous leg ulcers (“VLUs”), and other wound types, including those where the need exists to secure the graft in place with sutures. In addition, its product attributes and handling characteristics make it a preferable treatment option for deep or tunneling wounds.

About EPIXPRESS
EPIXPRESS is a lyophilized human placental-based allograft that includes the amnion layer, intermediate layer, and chorion layer. EPIXPRESS is intended for use as a barrier to provide a protective environment in acute and chronic wounds. The product provides a biocompatible human Extracellular Matrix (ECM) and contains 300+ regulatory proteins. Additionally, like MIMEDX’s other Wound products, including EPIFIX®, EPICORD®, EPIEFFECT®, CELERA™ and EMERGE™, EPIXPRESS is listed on the Medicare Part B Average Sales Price File. To learn more, please visit https://www.mimedx.com/EPIXPRESS/.

About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.

Contact:
Matt Notarianni
Investor Relations
470-304-7291
mnotarianni@mimedx.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.